Matthieu Delaye

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Cindy Neuzillet · 5 shared papers, 2023–2026 · strength 1.63
   • Paper Neoadjuvant approaches in non-metastatic pancreatic cancer: where do we stand? DOI 10.1016/s1470-2045(25)00421-8↗
   • Paper Current practices and challenges in the management of nonmetastatic pancreatic adenocarcinoma: results of an EORTC surv… DOI 10.1016/j.esmogo.2026.100372↗
   • Paper Toward Precision Chemotherapy for Pancreatic Cancer Guided by Transcriptomic Signatures. DOI 10.1002/ueg2.70124↗
2. Brice Chanez · 2 shared papers, 2025–2026 · strength 0.55
   • Paper Toward Precision Chemotherapy for Pancreatic Cancer Guided by Transcriptomic Signatures. DOI 10.1002/ueg2.70124↗
   • Paper Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: th… DOI 10.1016/j.dld.2026.10.006↗
3. Victoire Cardot‐Ruffino · 2 shared papers, 2023–2026 · strength 0.44
   • Paper Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: th… DOI 10.1016/j.dld.2026.10.006↗
   • Paper The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy. DOI 10.1016/s2468-1253(23)00207-8↗
4. Marc Hilmi · 2 shared papers, 2023–2026 · strength 0.44
   • Paper Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: th… DOI 10.1016/j.dld.2026.10.006↗
   • Paper The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy. DOI 10.1016/s2468-1253(23)00207-8↗
5. F. Huguet · 1 shared paper, 2026 · strength 0.36
   • Paper Current practices and challenges in the management of nonmetastatic pancreatic adenocarcinoma: results of an EORTC surv… DOI 10.1016/j.esmogo.2026.100372↗
6. Ingrid Garajová · 1 shared paper, 2026 · strength 0.36
   • Paper Current practices and challenges in the management of nonmetastatic pancreatic adenocarcinoma: results of an EORTC surv… DOI 10.1016/j.esmogo.2026.100372↗
7. Christelle Bouchart · 1 shared paper, 2026 · strength 0.36
   • Paper Current practices and challenges in the management of nonmetastatic pancreatic adenocarcinoma: results of an EORTC surv… DOI 10.1016/j.esmogo.2026.100372↗
8. António Sá Cunha · 1 shared paper, 2026 · strength 0.36
   • Paper Current practices and challenges in the management of nonmetastatic pancreatic adenocarcinoma: results of an EORTC surv… DOI 10.1016/j.esmogo.2026.100372↗
9. Nicolas Alejandro Fraunhoffer · 1 shared paper, 2025 · strength 0.30
   • Paper Toward Precision Chemotherapy for Pancreatic Cancer Guided by Transcriptomic Signatures. DOI 10.1002/ueg2.70124↗
10. Juan Iovanna · 1 shared paper, 2025 · strength 0.30
    • Paper Toward Precision Chemotherapy for Pancreatic Cancer Guided by Transcriptomic Signatures. DOI 10.1002/ueg2.70124↗
11. Nelson Dusetti · 1 shared paper, 2025 · strength 0.30
    • Paper Toward Precision Chemotherapy for Pancreatic Cancer Guided by Transcriptomic Signatures. DOI 10.1002/ueg2.70124↗
12. Gaël S. Roth · 1 shared paper, 2026 · strength 0.24
    • Paper Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: th… DOI 10.1016/j.dld.2026.10.006↗
13. Déwi Vernerey · 1 shared paper, 2026 · strength 0.24
    • Paper Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: th… DOI 10.1016/j.dld.2026.10.006↗
14. Jean‐Baptiste Bachet · 1 shared paper, 2026 · strength 0.24
    • Paper Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: th… DOI 10.1016/j.dld.2026.10.006↗
15. Nicolas Williet · 1 shared paper, 2026 · strength 0.24
    • Paper Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: th… DOI 10.1016/j.dld.2026.10.006↗
16. Olivier Bouché · 1 shared paper, 2026 · strength 0.24
    • Paper Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: th… DOI 10.1016/j.dld.2026.10.006↗
17. Anthony Tarabay · 1 shared paper, 2026 · strength 0.24
    • Paper Lung-only metastatic pancreatic cancer: Differences in patients 'characteristics, molecular profile and survival. DOI 10.1016/j.ejca.2026.116227↗
18. Cristina Smolenschi · 1 shared paper, 2026 · strength 0.24
    • Paper Lung-only metastatic pancreatic cancer: Differences in patients 'characteristics, molecular profile and survival. DOI 10.1016/j.ejca.2026.116227↗
19. Antoine Hollebecque · 1 shared paper, 2026 · strength 0.24
    • Paper Lung-only metastatic pancreatic cancer: Differences in patients 'characteristics, molecular profile and survival. DOI 10.1016/j.ejca.2026.116227↗
20. Alice Boilève · 1 shared paper, 2026 · strength 0.24
    • Paper Lung-only metastatic pancreatic cancer: Differences in patients 'characteristics, molecular profile and survival. DOI 10.1016/j.ejca.2026.116227↗
21. Michel Pierre Ducreux · 1 shared paper, 2026 · strength 0.24
    • Paper Lung-only metastatic pancreatic cancer: Differences in patients 'characteristics, molecular profile and survival. DOI 10.1016/j.ejca.2026.116227↗
22. Aurélien Lambert · 1 shared paper, 2026 · strength 0.24
    • Paper Lung-only metastatic pancreatic cancer: Differences in patients 'characteristics, molecular profile and survival. DOI 10.1016/j.ejca.2026.116227↗
23. Rémy Nicolle · 1 shared paper, 2023 · strength 0.19
    • Paper The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy. DOI 10.1016/s2468-1253(23)00207-8↗
24. Jerome F. Cros · 1 shared paper, 2023 · strength 0.19
    • Paper The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy. DOI 10.1016/s2468-1253(23)00207-8↗
25. Milena Muzzolini · 1 shared paper, 2023 · strength 0.19
    • Paper The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy. DOI 10.1016/s2468-1253(23)00207-8↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.